P-1

Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office

Retrieved on: 
Wednesday, March 20, 2024
Research, Composition, Nerve, Innovation, Psychological trauma, University, P-1, Patent, Stroke, MDXX, TBI, Cell membrane, United States patent law, Traumatic brain injury, OTC, MDMA, Pharmaceutical industry

“The molecule has an excellent therapeutic window; it shows a strong pro-social signal at dosage levels far below racemic MDMA.

Key Points: 
  • “The molecule has an excellent therapeutic window; it shows a strong pro-social signal at dosage levels far below racemic MDMA.
  • P-1 was submitted to the USPTO through the Patent Prosecution Highway program, allowing for accelerated patent examination.
  • As the molecule is ready for pre-clinical and clinical development, the Company has elected to change its designation to APA-001.
  • In addition there is potential applicability for the fear disorders often discussed in the context of MDMA.”

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

Retrieved on: 
Monday, January 8, 2024
MDXX, Conference, Partnership, PPH, PCT, Research, Patent, MDMA, University, Innovation, Patient, Safety, P-1, OTC, United States patent law, Pharmacology, Patent Cooperation Treaty, Pharmaceutical industry

“The dawn of MDMA as a therapeutic molecule is just beginning, and while we are actively working to treat patients with that molecule, we are also looking towards a future with novel molecular assets,” said Nick Kadysh, CEO, PharmAla Biotech.

Key Points: 
  • “The dawn of MDMA as a therapeutic molecule is just beginning, and while we are actively working to treat patients with that molecule, we are also looking towards a future with novel molecular assets,” said Nick Kadysh, CEO, PharmAla Biotech.
  • “P-1 is one of a number of next-generation assets which we are developing, and which promise to bring together both increased safety, and highly beneficial effects like increased neuroplasticity.”
    The Patent Prosecution Highway (PPH) speeds up the examination process for corresponding applications filed in participating intellectual property offices.
  • Under PPH, participating patent offices have agreed that when an applicant receives a ruling from a first patent office indicating that at least one claim is allowable, the applicant may request fast track examination of corresponding claims.
  • Proof-of-concept testing for P-1 showed significant efficacy and pro-social effect at dosage levels far lower than MDMA, PharmAla’s primary comparator molecule, as well as excellent safety pharmacology.

PharmAla Receives First Office Action for PharmAla-1 PCT Filing

Retrieved on: 
Monday, September 25, 2023
BIO, Intellectual property, Ontario Centre of Forensic Sciences, Partnership, CSE, University, P-1, Prior art, Medicine, University of Arkansas for Medical Sciences, Medication, MDXX, Innovation, Research, Patent Cooperation Treaty, PCT, CNS, Central nervous system, OTC, Toxicology, MDMA, Pharmacology, Safety, Pharmaceutical industry

VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has received the first office action from the Patent Cooperation Treaty (PCT) filing for the company’s novel PharmAla-1 (P-1) molecule.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is proud to announce that it has received the first office action from the Patent Cooperation Treaty (PCT) filing for the company’s novel PharmAla-1 (P-1) molecule.
  • “The generation of novel intellectual property is incredibly important for drug discovery companies like PharmAla.
  • This First Office Action for P-1 shows that our drug discovery pipeline yields novel, inventive molecules with significant value as neuropsychiatric therapeutics,” said Nick Kadysh, CEO, PharmAla Biotech.
  • “Our development pipeline, which can yield new molecules appropriate for pre-clinical development, is an incredible asset for PharmAla.

VisaLex Releases New Version of Its Platform, Further Streamlining the U.S. Immigration Process

Retrieved on: 
Thursday, March 9, 2023
Request, H-1B, USCIS, E-2, IPad, Acquisition, Visa policy of the United States, PDF, Naturalization, Organization, EB-1A, IPhone, EB-5, NIW, EB-2, Visa, Confusion, Android, RFE, Request for Evidence, O-1, United States Citizenship and Immigration Services, Translation, P-1, Mobile phone

ORLANDO, Fla., March 9, 2023 /PRNewswire-PRWeb/ -- VisaLex, a technology provider of online services that streamline the U.S. immigration process, announced today the launch of a significant update to its platform. Founded in 2017, VisaLex has helped more than 5,000 clients successfully apply for complex employment-based visas, as well as green cards. The company completely overhauled its platform during the pandemic, improving not only the user interface and user experience of all features, but also optimizing and further streamlining the application process.

Key Points: 
  • ORLANDO, Fla., March 9, 2023 /PRNewswire-PRWeb/ -- VisaLex, a technology provider of online services that streamline the U.S. immigration process, announced today the launch of a significant update to its platform.
  • Founded in 2017, VisaLex has helped more than 5,000 clients successfully apply for complex employment-based visas, as well as green cards.
  • The company completely overhauled its platform during the pandemic, improving not only the user interface and user experience of all features, but also optimizing and further streamlining the application process.
  • Citizenship and Immigration Services (USCIS) PDF documents, instantly converting them into an easy-to-use online form for applicants.

Desktop Metal and Lumafield Introduce Supply Chain Resilience Solution to Help Manufacturers Easily Scan and 3D Print Parts

Retrieved on: 
Monday, May 16, 2022
Automotive Manufacturing, Consumer Electronics, Aerospace, Technology, Manufacturing, Other Technology, Other Manufacturing, Software, Engineering, Mobile, Wireless, Hardware, CAD, Voyager, U.S. Securities and Exchange Commission, CT, Neptune, Multimedia, DLP, Solution, Metal, Studio, World Economic Forum, AM, P-1, Robotics, Technology, DM, Metallurgy, ETEC, Forward-looking statement, Biomaterial, Temperature, MIT Technology Review, Adoption, Joe Biden, 3D, Elastomer, Entrepreneurship, COVID, NYSE, Supply, CEO, Plastic, P4K, Supply chain resilience, 3D printing, Medical imaging, Desktop Metal

The Supply Chain Resilience package from Desktop Metal and Lumafield closes that gap by joining 3D printing with X-ray computed tomography, also known as CT scanning.

Key Points: 
  • The Supply Chain Resilience package from Desktop Metal and Lumafield closes that gap by joining 3D printing with X-ray computed tomography, also known as CT scanning.
  • The combination of these technologies allows manufacturers to scan old parts and reproduce them quickly in a variety of materials using 3D printing.
  • Customers interested in pairing a Lumafield scanner with a Desktop Metal printer can customize the solution that best fits their needs.
  • The Supply Chain Resilience package is available to any company that purchases a Desktop Metal 3D printer and reserves a Lumafield CT scanner between May 1 and July 1, 2022.

Desktop Metal to Showcase a Historic Collection of 300+ 3D Printed Production Parts Across the Industry’s Widest Portfolio of Materials at RAPID + TCT in Detroit

Retrieved on: 
Wednesday, May 11, 2022
Other Manufacturing, Technology, Textiles, Steel, Engineering, Other Technology, Automotive Manufacturing, Aerospace, Manufacturing, Hardware, Printing, Metal, Electronics, RAPID, NYSE, Deathmatch, Single-pass bore finishing, SPJ, Toyota Production System, Time, Software, Ford Motor Company, Dunton Technical Centre, International Conference on Mechanical Industrial & Energy Engineering, Ceramic, COVID, COVID-19 policy of the Joe Biden administration, DM, Industry, Sand, Adoption, Desktop Metal, Hong Kong Polytechnic University, C F Booth, P-1, Method, Production system, Elastomer, CEO, Technology, Team, Entrepreneurship, 3D, Collection, P-50, Multimedia, 3D printing

View the full release here: https://www.businesswire.com/news/home/20220511005615/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220511005615/en/
    Desktop Metal will showcase more than 300 3D printed parts across its metal, polymer, elastomer, ceramic, sand, and upcycled wood material portfolio.
  • The parts were 3D printed on the companys Additive Manufacturing 2.0 platforms.
  • (Photo: Business Wire)
    Desktop Metals parts and printer collection, which will greet attendees in Booth No.
  • A high-speed 3D printing system for end-use metal parts, the P-1 was designed as a gateway to the top-of-the-line Production System P-50 the worlds fastest system to 3D print metal parts at scale.